Prot #ACP-103-035: A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Project: Research project

Project Details

StatusActive
Effective start/end date9/12/179/12/20

Funding

  • Quintiles, Inc. (Prot #ACP-103-035)
  • ACADIA Pharmaceuticals Inc. (Prot #ACP-103-035)